Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Hoth Therapeutics, Inc.

Hoth Therapeutics develops innovative treatments aimed at improving patient quality of life. The company focuses on creating impactful and ground-breaking therapies.

Hoth Therapeutics

At Hoth Therapeutics, Inc.  (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Hoth Therapeutics, Inc

Are you registered for NobleCon? Make sure to catch our CEO, Robb Knie, as he presents at Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, College of Business, Executive Education Complex, December 3-5.
ATTENDEE REGISTRATION: https://lnkd.in/eQJf5HS8

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	188 -	28.25K 14,927.66%	31.62K 11.93%	25.87K 18.19%	46.87M 181,071.97%	66.83K 99.86%
gross profit	-188 -	-28.25K 14,927.66%	-31.62K 11.93%	-25.87K 18.19%	-46.87M 181,071.97%	-66.83K 99.86%
selling and marketing expenses	964.33K -
general and administrative expenses	320.12K -	1.22M 281.37%	5.06M 314.16%	3.96M 21.70%	6.57M 66.01%	6.13M 6.66%	4.21M 31.33%
selling general and administrative expenses	1.28M -	1.22M 4.95%	5.06M 314.16%	3.96M 21.70%	6.57M 66.01%	6.13M 6.66%	4.21M 31.33%
research and development expenses	586.84K -	1.02M 73.12%	2.12M 108.68%	2.89M 36.26%	7.53M 160.63%	4.93M 34.51%	3.48M 29.43%
other expenses		258.71K -	538.58K 108.18%	454.21K 15.67%	-212.26K 146.73%	451.14K 312.54%
cost and expenses	1.87M -	2.50M 33.34%	7.71M 209.15%	7.30M 5.35%	14.10M 93.12%	11.07M 21.53%	7.69M 30.48%
operating expenses	1.87M -	2.50M 33.36%	7.71M 209.15%	7.30M 5.35%	14.10M 93.12%	11.07M 21.53%	7.69M 30.48%
interest expense						305.41K -
ebitda	-1.87M -	-2.49M 33.29%	-7.72M 209.67%	-7.30M 5.48%	-14.10M 93.15%	-10.68M 24.27%	-7.69M 27.97%
operating income	-1.87M -	-2.50M 33.34%	-7.71M 209.15%	-7.30M 5.35%	-14.10M 93.12%	-11.07M 21.53%	-7.69M 30.48%
depreciation and amortization	188 -	1.22K 551.06%	-9.11K 844.36%	1.04K 111.45%	1.04 99.90%	386.91K 37,095,681.40%
total other income expenses net	-144K -		10.36K -	104.16K 905.29%	-212.26K 303.79%	-306.40K 44.35%	-153.15K 50.02%
income before tax	-2.02M -	-2.50M 23.82%	-7.70M 208.74%	-7.20M 6.58%	-14.31M 98.86%	-11.37M 20.55%	-7.85M 31.01%
income tax expense	2 -		-10.36K -		-1.04 -	305.41K 29,281,883.33%
net income	-2.02M -	-2.50M 23.82%	-7.69M 208.32%	-7.20M 6.45%	-14.31M 98.86%	-11.68M 18.42%	-7.85M 32.82%
weighted average shs out	384.48K -	376.98K 1.95%	366.58K 2.76%	494.51K 34.90%	893.20K 80.62%	1.20M 34.07%	3.41M 184.69%
weighted average shs out dil	384.48K -	376.98K 1.95%	366.58K 2.76%	494.51K 34.90%	893.20K 80.62%	1.20M 34.07%	3.41M 184.69%
eps	-5.24 -	-6.62 26.34%	-20.99 217.07%	-14.56 30.63%	-16.03 10.10%	-9.75 39.18%	-2.30 76.41%
epsdiluted	-5.24 -	-6.62 26.34%	-20.99 217.07%	-14.56 30.63%	-16.03 10.10%	-9.75 39.18%	-2.30 76.41%

NASDAQ:HOTH

Hoth Therapeutics

Last Close

0.86

25/09 14:34

Market Cap

4.91M

Beta: 0.12

Volume Today

93.74K

Avg: 729.84K

PE Ratio

−0.48

PFCF: −0.75

Preview